Feline cancer testing · October 13, 2026
CanCan launches a tumor sequencing panel for cats
CanCan Diagnostics has launched a tumor sequencing panel for cats. Its feline Tissue Core test examines 75 cancer-related genes in a tumor sample, looking for mutations that may help explain the tumor’s biology and identify potential targets for treatment.
What the test looks for
The panel reads selected parts of the tumor’s DNA. It includes oncogenes, genes that can drive cancer growth when altered, and tumor suppressor genes, which normally help control cell growth. The purpose is to give the oncologist molecular information about the individual tumor, alongside its pathology and the rest of the cancer workup.
A finding may point to a molecular pathway that a drug could act on. We asked CanCan whether its report actually suggests treatments. The team confirmed that it does, while emphasizing that evidence in cats is currently very limited. They draw on human and canine oncology research and state when a suggested drug has not been tested in cats.
That distinction matters: finding a possible target does not show that the drug will help a particular cat, or establish its safety and dose. Those questions still need assessment by the treating oncologist. The panel offers potential treatment leads, rather than a proven treatment plan.
Samples, turnaround and cost
According to the official feline brochure, the laboratory accepts formalin-fixed, paraffin-embedded tumor tissue (FFPE) or suitable fine-needle aspirate (FNA) slides. Material already collected for biopsy, surgery or cytology may be usable if it meets the laboratory’s requirements.
The brochure requests five 5-micrometer tissue sections or three to five cellular FNA slides, with at least 30% tumor content. Stained slides can be used. The veterinarian or pathologist should confirm suitability before submission; decalcification may compromise DNA quality. The listed turnaround is up to three weeks.
In direct correspondence on October 13, 2026, CanCan quoted a total test cost of £300 / $400 and said it has patients from around the world. The reply did not itemize shipping or veterinary and pathology preparation charges. Owners should ask their veterinarian and the company about the full cost and the submission route from their country.
Feline treatment studies are still being organized
CanCan said it is discussing feline drug safety and dosing studies with several academic partners, but the work remains at the organizational stage. The team did not disclose sites or specific drugs and offered to notify us when patient recruitment begins.
This currently available tissue panel is separate from CanCan’s planned feline liquid biopsy. The brochure lists the blood-based test as coming in the second quarter of 2027; it should not be confused with the tissue test described here.
Veterinarians can request sample and ordering information at enquiries@cancandiagnostics.com. Owners can also compare this service with the other options in our Genomic tests directory.